BGT.AX ASX
Bio-Gene Technology Limited
1W: -5.9%
1M: -11.1%
3M: -5.9%
YTD: -52.9%
1Y: -27.3%
3Y: -82.2%
5Y: -88.6%
A$0.02 ($0.01)
+0.00 (+0.00%)
Weekly Expected Move ±7.9%
A$0
A$0
A$0
A$0
A$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$42K
+82.9% ▲
Operating Income
-$3M
-11.1% ▼
Net Income
-$2M
+9.8% ▲
EPS (Diluted)
$-0.01
+38.5% ▲
EBITDA
-$3M
-30.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $446K | $149K | $18K | $0 | $0 |
| YoY Growth | +611.9% | -66.5% | -87.7% | -100.0% | +0.0% |
| Cost of Revenue | $267K | $313K | $320K | $246K | $42K |
| Gross Profit | $179K | -$164K | -$301K | -$246K | -$42K |
| Gross Margin | 40.1% | -109.9% | -1645.5% | — | — |
| R&D Expenses | $2M | $2M | $1M | $1M | $2M |
| SG&A Expenses | $1M | $1M | $2M | $1M | $2M |
| Operating Expenses | $4M | $3M | $3M | $3M | $3M |
| Operating Income | -$3M | -$4M | -$3M | -$3M | -$3M |
| Operating Margin | -764.5% | -2431.0% | -16716.5% | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$3M | -$3M | -$3M | -$3M | -$3M |
| Tax Expense | -$434K | -$446K | -$604K | -$386K | -$470K |
| Net Income | -$3M | -$3M | -$2M | -$3M | -$2M |
| Net Margin | -653.8% | -2074.5% | -13150.5% | — | — |
| EPS (Diluted) | $-0.02 | $-0.02 | $-0.01 | $-0.01 | $-0.01 |
| EBITDA | -$3M | -$3M | -$3M | -$3M | -$3M |
| Shares Outstanding | 153M | 168M | 186M | 211M | 309M |